U.S. FDA Approves Eisai Oral Aloxi For Preventing CINV
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai said Aug. 24 that it had obtained U.S. FDA approval for an oral capsule formulation of Aloxi (palonosetron) for preventing chemotherapy-induced nausea and voting, broadening the company's reach into the CINV market